Tabula Rasa HealthCare (NASDAQ:TRHC) Rating Increased to Strong-Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a hold rating to a strong-buy rating in a report published on Friday morning, Zacks.com reports. The brokerage currently has $72.00 price objective on the stock.

According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “

A number of other equities research analysts have also recently commented on TRHC. Piper Jaffray Companies increased their price objective on shares of Tabula Rasa HealthCare from $73.00 to $78.00 and gave the company an overweight rating in a research note on Thursday, May 9th. TheStreet cut shares of Tabula Rasa HealthCare from a c- rating to a d+ rating in a research note on Tuesday, June 11th. Cantor Fitzgerald reissued a buy rating and issued a $99.00 price objective on shares of Tabula Rasa HealthCare in a research note on Monday, May 13th. ValuEngine raised shares of Tabula Rasa HealthCare from a hold rating to a buy rating in a research note on Thursday, July 11th. Finally, BidaskClub raised shares of Tabula Rasa HealthCare from a buy rating to a strong-buy rating in a research note on Tuesday, August 13th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. Tabula Rasa HealthCare presently has a consensus rating of Buy and an average target price of $83.12.



NASDAQ:TRHC opened at $63.54 on Friday. The company has a quick ratio of 1.73, a current ratio of 1.97 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare has a fifty-two week low of $40.86 and a fifty-two week high of $91.16. The stock has a market cap of $1.40 billion, a PE ratio of 186.88 and a beta of 1.63. The firm’s fifty day simple moving average is $56.83 and its 200-day simple moving average is $53.84.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.29. Tabula Rasa HealthCare had a negative net margin of 7.09% and a positive return on equity of 3.63%. The business had revenue of $76.26 million for the quarter, compared to analysts’ expectations of $70.40 million. During the same period in the prior year, the company posted $0.20 EPS. The business’s revenue for the quarter was up 56.9% on a year-over-year basis. Equities analysts anticipate that Tabula Rasa HealthCare will post -0.14 earnings per share for the current year.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $56.23, for a total value of $449,840.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gordon Tunstall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $62.64, for a total transaction of $62,640.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,000 shares of company stock worth $2,800,120. 11.80% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. Intrinsic Edge Capital Management LLC lifted its holdings in Tabula Rasa HealthCare by 173.3% in the 2nd quarter. Intrinsic Edge Capital Management LLC now owns 358,673 shares of the company’s stock valued at $17,909,000 after purchasing an additional 227,453 shares in the last quarter. Royal Bank of Canada lifted its holdings in Tabula Rasa HealthCare by 250.7% in the 2nd quarter. Royal Bank of Canada now owns 3,812 shares of the company’s stock valued at $191,000 after purchasing an additional 2,725 shares in the last quarter. Nuveen Asset Management LLC purchased a new position in Tabula Rasa HealthCare in the 2nd quarter valued at about $3,398,000. Price T Rowe Associates Inc. MD lifted its holdings in Tabula Rasa HealthCare by 18.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,315,216 shares of the company’s stock valued at $65,669,000 after purchasing an additional 202,683 shares in the last quarter. Finally, Centaurus Financial Inc. lifted its holdings in Tabula Rasa HealthCare by 16.8% in the 2nd quarter. Centaurus Financial Inc. now owns 3,965 shares of the company’s stock valued at $198,000 after purchasing an additional 571 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: Why are percentage decliners important?

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.